BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 33055468)

  • 21. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
    Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
    Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen.
    Londoño MC; Lens S; Mariño Z; Bonacci M; Ariza X; Broquetas T; Pla A; Bartres C; Adriani MV; Rodríguez-Tajes S; Costa J; Carrión JA; Pérez-Del-Pulgar S; Forns X
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1156-1161. PubMed ID: 28206681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
    Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
    World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hepatitis B virus reactivation in rituximab-treated patients: incidence and risk factors].
    Gutiérrez García ML; Alonso Lopez S; Martín Rios MD; Sanmartin Fenollera P; Agudo Fernandez S; Fernández Rodriguez CM
    Gastroenterol Hepatol; 2015 Jan; 38(1):1-6. PubMed ID: 25205080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
    Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
    Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hepatits B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy and effective prophylactic management: a prospective observational study in a hospital over an 8-year period].
    Notsumata K; Matsukawa H; Yamakawa G; Nomura Y; Nomura K; Ueda T; Sanada T; Watanabe H; Toya D
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(11):1038-1046. PubMed ID: 34759100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma.
    Loglio A; Viganò M; Grossi G; Labanca S; Goldaniga M; Pompa A; Farina L; Rumi M; Corradini P; Facchetti F; Lunghi G; Baldini L; Lampertico P
    Dig Liver Dis; 2019 Mar; 51(3):419-424. PubMed ID: 30316785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
    Tan J; Zhou J; Zhao P; Wei J
    Clin Rheumatol; 2012 Aug; 31(8):1169-75. PubMed ID: 22544263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
    Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
    World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis.
    Wang J; Hu C; Chen Y; Liu Z; Yu Q; Yang S; Dong J; Yang Y; Wu Y; Ren D; Yao N; Guo D; Tian Z; Zhao Y; Chen T; He Y; Liu J
    Antivir Ther; 2019; 24(2):77-84. PubMed ID: 30833515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
    Rodríguez-Tajes S; Miralpeix A; Costa J; López-Suñé E; Laguno M; Pocurull A; Lens S; Mariño Z; Forns X
    J Viral Hepat; 2021 Jan; 28(1):89-94. PubMed ID: 32969557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience.
    Oh MJ; Lee HJ
    Clin Mol Hepatol; 2013 Mar; 19(1):51-9. PubMed ID: 23593610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
    J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Nishimura D; Goto H; Hirooka Y
    Clin J Gastroenterol; 2016 Aug; 9(4):252-6. PubMed ID: 27329484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
    Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
    Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation.
    Lee J; Park JY; Kim DG; Lee JY; Kim BS; Kim MS; Il Kim S; Kim YS; Huh KH
    Sci Rep; 2018 Oct; 8(1):15629. PubMed ID: 30353021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: a case report and literature review.
    Ferreira R; Carvalheiro J; Torres J; Fernandes A; Giestas S; Mendes S; Agostinho C; Campos MJ
    Saudi J Gastroenterol; 2012; 18(4):277-81. PubMed ID: 22824772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.